New drug combo shows promise for rare salivary gland cancer
NCT ID NCT04325828
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests whether a combination of two hormone-blocking drugs (apalutamide and a GnRH agonist) can shrink or slow the growth of advanced salivary gland cancer that has a specific protein called the androgen receptor. About 31 adults with locally advanced or spread cancer that has this receptor will receive the treatment. The main goal is to see how many patients have their tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aichi Cancer Center Hospital
Nagoya, 464 8681, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Kansai Medical University Hospital
Hirakata, 573 1191, Japan
-
National Cancer Center Hospital
Chūōku, 104 0045, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, 810 8563, Japan
-
National Hospital Organization Shikoku Cancer Center
Matsuyama, 791 0280, Japan
-
Niigata University Medical And Dental Hospital
Niigata, 951 8520, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- New PET tracer could spot cancers that standard scans overlook
- Drug duo takes on rare head and neck tumors
- New pill-chemo combo takes on hard-to-treat cancers
- Common pain gel could shield cancer patients from radiation burns
- Scientists hunt for immune clues in rare salivary gland cancers